1. Extended Prevalence of Infection in ICU Study (EPIC II) Group of Investigators. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study;Kett;Crit Care Med,2011
2. Systemic antifungal therapy in critically ill patients without invasive fungal infection*;Azoulay;Crit Care Med,2012
3. Attributable mortality of nosocomial candidemia, revisited;Gudlaugsson;Clin Infect Dis,2003
4. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia;Arendrup;J Clin Microbiol,2011
5. Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron M, et al. Msg-01: A multicenter, randomized, double-blind, placebo controlled trial of caspofungin (cas) prophylaxis vs placebo followed by pre-emptive therapy for invasive candidiasis (ic) in high-risk adults in the critical care setting. Preliminary results. SHEA Annual Scientific Meeting. Dallas, Texas, United States; 2011.